

Sajad J Khazal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4182309/publications.pdf>

Version: 2024-02-01

56
papers

637
citations

759233

12
h-index

642732

23
g-index

57
all docs

57
docs citations

57
times ranked

901
citing authors

#	ARTICLE	IF	CITATIONS
1	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 45-63.	27.6	178
2	Minimal Residual Disease Detection in Acute Lymphoblastic Leukemia. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1054.	4.1	61
3	Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. <i>Lancet Haematology</i> , 2020, 7, e61-e72.	4.6	56
4	A pragmatic multi-institutional approach to understanding transplant-associated thrombotic microangiopathy after stem cell transplant. <i>Blood Advances</i> , 2021, 5, 1-11.	5.2	46
5	Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia. <i>Blood</i> , 2022, 139, 1908-1919.	1.4	34
6	Diagnosis, grading and management of toxicities from immunotherapies in children, adolescents and young adults with cancer. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 435-453.	27.6	31
7	Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. <i>Cancers</i> , 2022, 14, 150.	3.7	30
8	Immune Effector Cell Associated Neurotoxicity (ICANS) in Pediatric and Young Adult Patients Following Chimeric Antigen Receptor (CAR) T-Cell Therapy: Can We Optimize Early Diagnosis?. <i>Frontiers in Oncology</i> , 2021, 11, 634445.	2.8	23
9	Extracorporeal membrane oxygenation in children receiving haematopoietic cell transplantation and immune effector cell therapy: an international and multidisciplinary consensus statement. <i>The Lancet Child and Adolescent Health</i> , 2022, 6, 116-128.	5.6	17
10	VLA4 Blockade In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 3944-3944.	1.4	16
11	The PI3KÎ Inhibitor Idelalisib Inhibits Homing in an in Vitro and in Vivo Model of B ALL. <i>Cancers</i> , 2017, 9, 121.	3.7	14
12	Improved detection of sinusoidal obstructive syndrome using pediatricâ€“AYA diagnostic criteria and severity grading. <i>Bone Marrow Transplantation</i> , 2021, 56, 175-184.	2.4	13
13	Allogeneic hematopoietic stem cell transplantation is associated with cure and durable remission of lateâ€“onset primary isolated central nervous system hemophagocytic lymphohistiocytosis. <i>Pediatric Transplantation</i> , 2018, 22, e13101.	1.0	11
14	Am80â€“GCSF synergizes myeloid expansion and differentiation to generate functional neutrophils that reduce neutropeniaâ€“associated infection and mortality. <i>EMBO Molecular Medicine</i> , 2016, 8, 1340-1359.	6.9	10
15	Unrelated donor hematopoietic stem cell transplantation for the treatment of nonâ€“malignant genetic diseases: An alemtuzumab based regimen is associated with cure of clinical disease; earlier clearance of alemtuzumab may be associated with graft rejection. <i>American Journal of Hematology</i> , 2015, 90, 1021-1026.	4.1	9
16	Debate: Transplant Is Still Necessary in the Era of Targeted Cellular Therapy for Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 713-719.	0.4	9
17	Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. <i>Haematologica</i> , 2022, 107, 899-908.	3.5	9
18	Assessment of knowledge of vincristine toxicities in outpatient pediatric hematology/oncology nurses: An educational intervention.. <i>Journal of Clinical Oncology</i> , 2013, 31, 231-231.	1.6	8

#	ARTICLE	IF	CITATIONS
19	Complete remission in refractory acute lymphoblastic leukemia using blinatumomab after failure of response to CD19 chimeric antigen receptor T-cell therapy. <i>Clinical Case Reports (discontinued)</i> , 2020, 8, 1678-1681.	0.5	7
20	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. <i>Frontiers in Oncology</i> , 2021, 11, 625707.	2.8	7
21	Transfusion reactions in pediatric and adolescent young adult haematology oncology and immune effector cell patients. <i>EClinicalMedicine</i> , 2020, 26, 100514.	7.1	5
22	Primary mediastinal large B-cell lymphoma in paediatric and adolescent patients: emerging questions in the era of immunotherapy. <i>British Journal of Haematology</i> , 2020, 190, e114-e117.	2.5	5
23	Overcoming Psychosocial and Developmental Barriers to Blood and Marrow Transplantation (BMT) in an Adolescent/Young Adult (AYA) Transgender Patient with Chronic Myelogenous Leukemia. <i>Pediatric Hematology and Oncology</i> , 2014, 31, 765-767.	0.8	4
24	Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective. <i>Cancers</i> , 2022, 14, 2912.	3.7	4
25	5-azacitidine Monotherapy Followed by Related Haploidentical Hematopoietic Stem Cell Transplantation Achieves Durable Remission in a Pediatric Patient With Acute Undifferentiated Leukemia Refractory to High-dose Chemotherapy. <i>Pediatric Blood and Cancer</i> , 2016, 63, 1111-1112.	1.5	3
26	Allogeneic bone marrow transplantation for treatment of severe hemolytic anemia attributable to hexokinase deficiency. <i>Blood</i> , 2016, 128, 735-737.	1.4	3
27	Epstein-Barr virus specific cytotoxic T lymphocytes for the treatment of severe epstein-barr virus mucocutaneous ulcer. <i>British Journal of Haematology</i> , 2020, 189, e33-e36.	2.5	3
28	Incidence and Outcomes of Patients with Thrombotic Microangiopathy after Transplant: Results of Prospective Screening through a Multi-Institutional Collaborative. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S92.	2.0	3
29	Cytokine release syndrome and complete remission of extra medullary acute lymphoblastic leukemia of the breast with CAR-T and radiation therapy. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28839.	1.5	3
30	Hematopoietic cell transplantation for acute lymphoblastic leukemia: review of current indications and outcomes. <i>Leukemia and Lymphoma</i> , 2021, 62, 2831-2844.	1.3	3
31	Cardiac Relapse of Acute Lymphoblastic Leukemia Following Hematopoietic Stem Cell Transplantation: A Case Report and Review of Literature. <i>Cancers</i> , 2021, 13, 5814.	3.7	3
32	Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration. <i>Blood</i> , 2021, 138, 1247-1247.	1.4	3
33	The Role of Granulocyte Transfusions in Optimizing Candidacy for Chimeric Antigen Receptor T-Cell Therapy in Patients With Treatment-refractory Infections. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, Publish Ahead of Print, .	0.6	2
34	Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care. , 2019, , 1-13.		1
35	Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities. <i>Frontiers in Oncology</i> , 2020, 10, 1227.	2.8	1
36	Non-myeloablative umbilical cord blood transplantation for atypical dyskeratosis congenita. <i>Pediatric Transplantation</i> , 2021, , e14157.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Unrelated Donor Hematopoietic Stem Cell Transplantation for Treatment of Non-Malignant Genetic Diseases Using a Myeloablative Reduced Toxicity Conditioning Regimen. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S239.	2.0	0
38	Reduced Intensity Conditioning Followed By Allogeneic Hematopoietic Stem Cell Transplantation Resulted in Cure of a 15 Year Old Male with Primary Isolated CNS Late Onset Familial Hemophagocytic Lymphohistiocytosis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S347-S348.	2.0	0
39	5-Azacididine Monotherapy Followed By Related Haploidentical Hematopoietic Stem Cell Transplantation Achieves Durable Remission in a Pediatric Patient with Acute Undifferentiated Leukemia Refractory to High Dose Chemotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S206-S207.	2.0	0
40	Stable Mixed Donor Chimerism after Allogeneic Stem Cell Transplantation Using a Reduced Intensity Conditioning Regimen in a 4 Year Old Boy with Congenital Non Spherocytic Hemolytic Anemia Secondary to Hexokinase Deficiency. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S331.	2.0	0
41	High Dose Chemotherapy Followed by Autologous Stem Cell Rescue for High Risk Soft Tissue Sarcoma: Retrospective Review. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S138.	2.0	0
42	Bone Marrow Failure. , 2019, , 95-107.		0
43	Transfusion Reactions in Pediatric and Young Adult Hematopoietic Stem Cell Transplant and Oncology Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S149.	2.0	0
44	Care of the Critically Ill Pediatric Hematopoietic Cell Transplant Patient. , 2021, , 1207-1241.		0
45	Molecular Pathogenesis of Acute Lymphoblastic Leukemia. , 0, , 67-67.		0
46	PI3Kdelta Inhibitor, CAL-101, De-Adheres Primary Pre-B ALL from VCAM-1 and Induces Apoptosis in Primary Pre-B ALL. <i>Blood</i> , 2014, 124, 3715-3715.	1.4	0
47	The PI3Kdelta Inhibitor, CAL-101, Inhibits Migration of Primary Pre-B ALL to SDF1alpha: Treatment Implications for Overcoming Cell-Adhesion-Mediated Drug Resistance. <i>Blood</i> , 2015, 126, 2526-2526.	1.4	0
48	Abstract 1345: Automated capture and analysis of circulating tumor cells across different types of tumors in pediatric cancer patients. , 2019, , .		0
49	Chimeric Antigen Receptor (CAR) T-Cell Therapy in the Pediatric Critical Care. , 2020, , 2035-2047.		0
50	Sinusoidal Obstructive Syndrome Among Pediatric and Adolescent and Young Adult Patients: Analysis of Pediatric EBMT Diagnostic and Severity Criteria at MD Anderson. <i>Blood</i> , 2019, 134, 4495-4495.	1.4	0
51	IMMU-07. IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) AMONG PEDIATRIC AND AYA PATIENTS: MD ANDERSON CANCER CENTER EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, iii361-iii361.	1.2	0
52	Immune Effector Cell Associated Neurotoxicity (ICANS) Among Pediatric and AYA Patients: MD Anderson Cancer Center Experience. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S316.	2.0	0
53	DNMT3A Mutations Should be Considered in the Risk Stratification for Pediatric and Adolescent and Young Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 1308-1308.	1.4	0
54	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 17-18.	1.4	0

#	ARTICLE	IF	CITATIONS
55	IMMU-52. IMMUNE EFFECTOR CELL ASSOCIATED NEUROTOXICITY (ICANS) AMONG PEDIATRIC AND AYA PATIENTS: MD ANDERSON CANCER CENTER EXPERIENCE. <i>Neuro-Oncology</i> , 2020, 22, ii116-ii116.	1.2	0
56	Abstract 1345: Automated capture and analysis of circulating tumor cells across different types of tumors in pediatric cancer patients. , 2019, , .		0